Teijin Pharma President To Become Group President
This article was originally published in PharmAsia News
Executive Summary
Teijin Pharma President Nario Oyagi is slated to be the new president of Teijin Group, and he is scheduled to be elected during the June 20 shareholders meeting. Oyagi joined the firm in 1971; he has since served as director for medical planning and general manager of medical business. Oyagi became president of Teijin Pharma in 2003. Discussing future visions for Teijin Pharma, Oyagi expects to expand worldwide into the home healthcare arena. Teijin Pharma has established an office in New York City, and it will actively promote business in America, Europe and Asia. (Click here for more-Japanese language
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.